Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155 on ClinicalTrials.gov · last registry update 2025-12-23

Recruiting now, toward 70 participants. Due to report 1 February 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Change in SF-36 Physical Component Summary (PCS) Score From Baseline to 6 Months. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The Cleveland Clinic
Sponsor type: Other
Enrollment: 70
Started: 2025-12-17
Primary completion: 2029-02-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in SF-36 Physical Component Summary (PCS) Score From Baseline to 6 Months

Conditions studied

Liver Cirrhoses · Portal Hypertension Related to Cirrhosis · Severe Obesity · TIPS

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.